Erratum

A review of an emerging enteric pathogen: enteroaggregative *Escherichia coli*

David B. Huang, Alakananda Mohanty, Herbert L. DuPont, Pablo C. Okhuysen and Tom Chiang

Journal of Medical Microbiology (2006), 55, part 10, 1303–1311

The second paragraph of the ‘Treatment’ section on page 1308 is incorrect. The correct paragraph is below.

Two clinical trials have been conducted evaluating treatment of EAEC diarrhoea in travellers (Table 5). The first trial evaluated the clinical response of travellers with EAEC diarrhoea to ciprofloxacin (500 mg twice a day for 3 days) (Glandt *et al.*, 1999), and the second trial evaluated the clinical response to rifaximin (200 and 400 mg three times a day for 3 days), a poorly absorbed antimicrobial agent (Infante *et al.*, 2004). In the first trial, 29 of 64 (45 %) US travellers to Jamaica and Mexico developed diarrhoea due to EAEC. Sixteen of the patients were treated with ciprofloxacin and 13 with placebo. The patients treated with ciprofloxacin had a significant reduction in the duration of post-treatment diarrhoea (35 versus 56 h), and a non-significant reduction in the mean number of unformed stools passed during the 72 h after enrolment compared to patients who received placebo (six episodes versus eight episodes). The second trial was multicentred, and included 43 of 137 (32 %) US travellers to Guatemala, Kenya and Mexico who developed diarrhoea due to EAEC. Thirty of the patients were treated with rifaximin and 13 with placebo. The patients treated with rifaximin had a significant reduction in the duration of post-treatment diarrhoea compared to placebo (22 versus 72 h).

Some of the information in Table 5 on page 1309 is incorrect. The correct table is reproduced below.

Table 5. Clinical trials evaluating treatment of diarrhoea due to EAEC in travellers

TLUS, time to last unformed stool; NA, not applicable.

	Study one (Mexico, Jamaica)*		Study two (Mexico, Guatemala, Kenya)†	
Treatment	Ciprofloxacin (n=16)	Placebo (n=13)	Rifaximin (n=30)	Placebo (n=13)
Dosage	500 mg twice a day for 3 days	Four times a day for 2 days	200 or 400 mg three times a day for 3 days	Three times a day for 3 days
Median TLUS (h)	35.3	55.5	22.0	72.0
Microbiological cure	NA	NA	NA	NA

*Glandt *et al.* (1999).

†Infante *et al.* (2004).